NCI's Proposed IP Policy May Hinder Personalized Medicine, Stakeholders Say

NCI has outlined changes to its IP policies for collaborative research agreements that would essentially provide industry collaborators with first-option commercial licensing rights for IP arising from studies that make use of pharma companies' proprietary drugs, or samples from patients treated with those drugs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.